SkyePharma receives bid approach from UK drug group
SkyePharma, the perennially disappointing drug development company chaired by Ian Gowrie-Smith, is to sell itself to the highest bidder, after receiving an "unsolicited approach".
An unnamed UK drug company is believed to have suggested a merger last week, as SkyePharma shares languished near 10-year lows.
SkyePharma was forced into a humiliating rights issue last month after failing to find a funding partner for its latest asthma drug, and Michael Ashton, its long-standing chief executive has signalled his intention to retire. The company has appointed Lehman Brothers to conduct a "strategic review", which will attempt to encourage an auction of the company or will examine whether it should be sold off piece by piece.
The company said: "Following a recent unsolicited approach from a third party, the board has decided to review its strategic options, including inter alia offers for the company as a whole. There is no certainty that the review will result in any change to the present ownership structure."
SkyePharma shares had risen last week after the completion of its £35m rights issue and amid swirling rumours of a private equity bid. Traders noted that HBM Partners, a Swiss private-equity house had raised its stake to 6.6 per cent.
Industry sources suggested that the approach had come from a UK player, and the speculation was that a relatively small drug development company would want to bulk up by acquiring SkyePharma's drug-delivery technologies and manufacturing capability. Private equity participation in the auction would be a possibility, although SkyePharma's capital structure is complicated by debt which is convertible into equity and royalty income streams, which are shared with a finance house called Paul Capital.
The company specialises in developing ways of delivering drugs, particularly in controlled-release injections and pills, and in inhalers. The appointment of Lehman Brothers to conduct the strategic review is a snub to CSFB, its house broker, with whom Mr Gowrie-Smith had a falling out over the rights issue, which he regarded as priced too low. CSFB's own analyst suggested clients think twice before backing the fund-raising and removed the asthma drug, Flutiform, from his financial forecasts because of its failure to attract a Big Pharma backer.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies